Reflecting global interest in the field, Chinese radiopharma specialists PharmadaX Genesis, LNC Biotechnology and SmartNuclide have been on a winning streak to secure venture capital funding. Separately, Impact and Arnatar raised around $50m each in their latest venture capital- and private equity-backed fundraisings.

More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

A quicker regulatory process and strong clinical science for years have made Europe an early launching pad for many US medical device start-ups, and Krauth Medical, Germany's leading distributor, a natural partner. For Krauth itself, continued cost pressures on the German health care system necessitated the need for a strategic overhaul a couple of years ago. The company has shed some long-standing businesses and gotten into some new areas, including spine and aesthetic surgery.